CompletedNot Applicable

Photographic Imaging of the Retina and Optic Nerve Head of Glaucoma Patients and Normal Controls

Switzerland120 participantsStarted 2006-01

Plain-language summary

Retinal structures are difficult to visualize because the retina is optically transparent. In glaucoma, the microglia in the retina becomes activated in eyes with glaucomatous damage. The microglia forms a dense meshwork which resembles gliosis-like alterations, which may increase light scattering. With appropriate technology, increased reflection and light scattering from the retina may be detected in eyes of glaucoma patients. In this study, we investigate whether clinically observable retinal gliosis-like alterations occur more often in patients with glaucoma than in non-glaucomatous controls, and whether gliosis-like alterations are associated with a vasospastic propensity.

Who can participate

Age range45 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: For NTG patients : * untreated intraocular pressure equal to or less than 21mmHg or * median intraocular pressure equal to or less than 20mmHg For HTG patients: * mean untreated intraocular pressure more than 21mmHg For both: * open drainage angles on gonioscopy * typical optic disc damage with glaucomatous cupping and thinning of neuroretinal rim * absence of any secondary cause for a glaucomatous optic neuropathy * visual field defects congruent to glaucomatous disc damage (disc/field correlation) Healthy subjects: * no history of ocular diseases * no current topical medication * no drug or alcohol abuse * best corrected visual acuity above 20/25 in both eyes * no pathological findings upon a slit-lamp examination and fundoscopy * IOP \< 21 mmHg in both eyes Exclusion Criteria: For NTG and HTG patients: * any other form of retinal or neuroophthalmological disease that could cause gliosis-like retinal alterations or result in visual field defects * history of chronic or recurrent severe inflammatory eye disease * history of ocular trauma or intraocular surgery * history of infection or inflammation within the past 3 months * history and clinical evidence for other retinal disease

Trial details

NCT IDNCT00430274

SponsorSelim Orguel

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2009-08